Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
We are on track for a 100,000,000 volume day today! :D The momentum is real
Hopefully, we will break .20 after hours.
77,050,000 Volume as of 1:38pm! Amazing start to the week, I'm looking forward to more data to analyze :^)
sell now or forever hold your peace ;)
File bankruptcy please! Stop fooling shareholders funders
Something wrong with this stock ...gain keep evaporated not once but many times
Dammmm in .17 and it goes down.. ridiculous stock
Dammmm in .17 and it goes down.. ridiculous stock
Volume update: In the first 45 minutes of trading the volume spiked to 46,000,000 shares traded! I've been watching since this morning it was only at 2,000,000 before 8:30am EST! HUGE WEEK AHEAD
Nice moves today
Napo Pharmaceuticals, a Jaguar Health Family Company, to Exhibit at Oncology Nursing Society (ONS) Congress in Support of Company’s Expanding Focus on Cancer Supportive Care
https://ons.confex.com/ons/2024/meetingapp.cgi/Session/5984
.....then .25c booooooming
imo
lol seems to be a couple guys missing in here today ?
Someone is Frantically returning shorted shares LOL:
28 minutes ago 2024-04-22 13:29:20.55 3,200,000
2 hours ago 2024-04-22 11:55:25.082 3,100,000
4 hours ago 2024-04-22 09:50:03.526 3,400,000
4 hours ago 2024-04-22 09:18:35.106 5,100,000
5 hours ago 2024-04-22 08:47:21.366 4,000,000
9 hours ago 2024-04-22 04:35:34.433 4,100,000
1 day ago 2024-04-21 03:39:47.128 4,700,000
2 days ago 2024-04-20 05:14:52.981 4,500,000
2 days ago 2024-04-20 03:31:21.243 4,400,000
2 days ago 2024-04-20 00:52:15.895 4,300,000
That’s why can’t hold gain free ATM
Actually, if someone has proven to be unworthy of listening to, why bother with them??
Who cares what they think if they have confirmed they aren't trustworthy to read?
Just curious why some continue to interact with those that aren't 'value added'
Yes, they will have an exhibit at ONS, however it sounds like it's just to showcase the Gelclair. Results will not be released IMHO. However, this is still great news as they are building up their presence in the market.
It's funny actually, I don't think these idiots realize that spreading misinformation about a stock is Illegal. whew, good thing I've been documenting all the cry baby shorts for 3 months ;)
You are only telling lies buddy. I hope you have a huge short position, because this one is going to be your end
https://finance.yahoo.com/news/napo-pharmaceuticals-jaguar-health-family-124500876.html
NEWS is officially out for their upcoming conference 4/24-4/28!!
Company never had any intentions of getting this over a dollar. They will sell shares till August, then RS...CEO should be imprisoned.
Let the line out $$$$$$
Oddly enough I had a conversation with AI about JAGX, I didn't ask "WiLl ThE PrIcE gO Up?" . But I did ask it's opinion of Crofelemer given the current data and news available. This was it's response:
"If the Phase 3 trial for crofelemer is successful and it receives FDA approval, it has the potential to make a significant impact in the world. Crofelemer has already shown promise in providing relief for non-infectious diarrhea in adults with HIV/AIDS, and its approval could mean improved quality of life for those patients. Additionally, it could open doors for potential applications in other indications, further expanding its positive impact. It's exciting to think about the potential positive change crofelemer could bring! "
Borrow fee still at 60% , panic panic panic shorts !!!
I'm just going to leave this here lol, this isn't even all of the shorts returned. I have a good feeling about this week!
20 hours ago 2024-04-21 03:39:47.128 4,700,000
1 day ago 2024-04-20 05:14:52.981 4,500,000
1 day ago 2024-04-20 03:31:21.243 4,400,000
1 day ago 2024-04-20 00:52:15.895 4,300,000
2 days ago 2024-04-19 21:39:53.914 4,700,000
2 days ago 2024-04-19 19:31:14.485 4,600,000
2 days ago 2024-04-19 15:47:59.025 4,700,000
2 days ago 2024-04-19 12:36:25.092 3,700,000
2 days ago 2024-04-19 12:03:31.409 3,500,000
2 days ago 2024-04-19 09:54:24.314 3,600,000
JAGX the dreamer board wake up idiots
Wrong drug buddy
geez man insiders own 4.5%
tell it all .... dilution pos
and yet here YOU ARE working hard to save us from 'what'??
LOL...
What PR are you waiting on ? They just got FDA Approval and it's back to where it started from...Not the shorts, Company is the biggest POS ever ! Share selling scam
Thank you for providing this info oldstocks! Have a great weekend see you monday
9 Distributors listed for Dog FDA approved Canalevia-CA1
canalevia.com/distributor-information
I don't even try to guess when PR will happen.
Just assess the set up, if I believe the company is doing something for itself, something that will give the market a
reason to want shares (increasing revenue and potential profitability is my focus)... and I like the buy in price (ie,
not overvalued relative to a potential target price)
I buy and see what happens, reassessing my decision as things progress.. Sometimes management manages to pull it off, sometimes they stumble. and the ongoing re-assessment says, time to move on..
Only with time will I know if it was a good decision or not..
and while I say I don't guess on potential PR, I do let the chart tell me what the market IS doing with respect to trending... for instance, if it can hold 16 cents?? Something HAS changed... would be a step in the right direction, small, but a step none the less..
Good luck...
Agree, something that has lost a lot of value tends to have trapped folks who refused to sell on the way down.
and yes, it has to flush them out, but has had the chance to do that since April of 2023..
Don't see it being an 'easy' road from here on out. But as long as they give the market a REASON to buy/own shares (ie, new sales, new sources of revenue??), with TIME, it has a chance of working out for those that 'see' a potential opportunity.
There was CRMD back in the 2016 timeframe that no one wanted. Started buying at 30 cents/sh and down to 23 or so cents. (pre the 1-5 they had to do) Just taken a little longer than anticipated..(3+ years of delays beyond their control in CRMDs case)
So yeah, JAXG will likely suffer some price repression for the reason you mention. But as long as they can execute, one day we MAY have a reason to say, we got it right back in early 2024.. Good luck..
LMAO look at all these shares being returned, this isn't all of them but I know someone's down Millions because of this. *Yawn* keep trying to scare us it's not working
50 minutes ago 2024-04-19 21:39:53.914 4,700,000
2 hours ago 2024-04-19 19:31:14.485 4,600,000
6 hours ago 2024-04-19 15:47:59.025 4,700,000
9 hours ago 2024-04-19 12:36:25.092 3,700,000
10 hours ago 2024-04-19 12:03:31.409 3,500,000
12 hours ago 2024-04-19 09:54:24.314 3,600,000
13 hours ago 2024-04-19 08:49:03.831 2,000,000
15 hours ago 2024-04-19 06:38:04.653 1,900,000
17 hours ago 2024-04-19 05:00:52.462 1,700,000
18 hours ago 2024-04-19 03:56:25.237 1,500,000
Share price vs its Moving Average line...
Just an observation, but have noticed that when a share price gets too far ahead of the moving average line,
they like to get back together. Can either involve the share price falling back & the MA line trying to catch up or the MA line catching up with the share price running flat. Always hope for the latter, but usually get the first especially if the share price got over enthusiastic in its movement (as Jags recently did)..
Now that its in its 4th day of closing prices (includes the day of the 25 cent spike), its within 2 cents of its closing price 4 days ago. Thats not to bad if this price range of 16-18 cents holds for a few more days while the MA line catches up from around 13 cents..
disclaimer: hold some, looking for 25 cents as a first target at the moment based on the news of a potential revenue stream developing. Then there is the PH 3 Wild Card..
You mean, wake up to my free shares lol
hahah so much volume that the borrow rate fee went to N/A 😂
no run coming and if run comes i short the hell out of it
???? wake up bro
Followers
|
155
|
Posters
|
|
Posts (Today)
|
46
|
Posts (Total)
|
6245
|
Created
|
12/01/15
|
Type
|
Free
|
Moderators ProfitChaser oldstocks DTGoody powerbattles crudeoil24 SmellMyFinger |
Jaguar Health, Inc. $JAGX
Bringing Plant-based Medicines to Life™
Pharmaceutical Manufacturing
San Francisco, California
Jaguar Health’s organizational framework is designed to enable our product pipeline to reach the world’s interconnected marketplace, allowing for development and commercialization opportunities worldwide.
Products:
Mytesi Crofelemer 125mg delayed release tablets
Mytesi is FDA-approved for symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy
Market size of the FDA HIV Mytesi Crofelemer could be $25-$30 Million in the USA
Mytesi has a novel mechanism of action that modulates chloride secretion in the gastrointestinal tract, reducing excessive chloride and accompanying water flow and relieving watery diarrhea.
Mytesi is not indicated for the treatment of infectious diarrhea. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (6%), bronchitis (4%), cough (4%), flatulence (3%), and increased bilirubin (3%).
Canalevia-CA1 Crofelemer delayed release tablets
Distributors listed:
https://www.canalevia.com/distributor-information
CANALEVIA-CA1 is conditionally approved for the treatment of chemotherapy-induced diarrhea (CID) in dogs.
Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-552.
CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian. It is a violation of Federal Law to use this product other than as directed in the labeling.
Lytham Partners Investor Select Conference February 1st, 2024
https://wsw.com/webcast/lytham10/jagx/2084640
Pipeline: https://jaguar.health/pipeline/
How to calculate the value of drugs and biotech companies
https://www.baybridgebio.com/drug_valuation.html
About the Jaguar Health Family of Companies
Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, and bowel incontinence.
Jaguar family company Napo Pharmaceuticals focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states.
Napo Pharmaceuticals' crofelemer drug product candidate is the subject of the OnTarget study, a pivotal Phase 3 clinical trial for preventive treatment of chemotherapy-induced overactive bowel (CIOB) in adults with cancer on targeted therapy.
Jaguar family company Napo Pharmaceuticals focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states.
Napo Pharmaceuticals' crofelemer drug product candidate is the subject of the OnTarget study , a pivotal Phase 3 clinical trial for preventive treatment of chemotherapy-induced overactive bowel (CIOB) in adults with cancer on targeted therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative is focused on developing novel prescription medicines derived from plants for mental health indications.
A Case Report: Improved Control of Tyrosine Kinase Inhibitor-Induced Diarrhea
Despite the efficacy of tyrosine kinase inhibitors (TKIs) across multiple cancers, side effects including treatment-related diarrhea can impede a patient’s ability to reach therapeutic doses or stay on therapy.
Below, we present the case of a 72-year-old patient with metastatic papillary renal cell carcinoma recurrent despite nephrectomy.
Over the course of treatment, the patient received multiple different tyrosine kinase inhibitors with varying efficacy.
Treatment with the TKI cabozantinib after failure of two prior TKIs resulted in a clinical response with shrinkage of his nodal metastatic disease.
However, the severe treatment-related diarrhea refractory to conventional management required both dose holds and dose reductions of cabozantinib.
Off-label administration of crofelemer, a novel FDA-approved antidiarrheal agent, successfully controlled the treatment-related diarrhea and allowed resumption and partial dose increase of cabozantinib.
This case suggests that crofelemer could be a viable therapeutic strategy to address TKI-induced diarrhea.
9.8 million people
receive chemotherapy worldwide per year
Wilson B, Jacob S, Yap M, et al. Estimates of global chemotherapy demands and corresponding physician workforce requirements for 2018 and 2040: a population-based study. Lancet Oncol. 2019;20(6):769-780. doi:10.1016/S1470-2045(19)30163-9
Chemotherapy-induced
diarrhea occurs in
50%-80%
of treated patients
Stein A, Voigt W, Jordan K. Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Ther Adv Med Oncol. 2010;2(1):51-63. doi:10.1177/1758834009355164
Patients with cancer therapy–
related diarrhea (CTD) were
40% more likely to
discontinue chemotherapy or
targeted cancer therapy than
patients without CTD
Okhuysen PC, Schwartzberg LS, Roeland E, et al. The impact of cancer-related diarrhea on changes in cancer therapy patterns. J Clin Oncol. 2021;39(15):12111. doi:10.1200/JCO.2021.39.15_suppl.12111
Research & Development
In October 2020, Napo Pharmaceuticals initiated a pivotal Phase 3 clinical trial
This Phase 3 study is evaluating crofelemer for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy
The principal investigator and co-investigators identified are from MD Anderson Cancer Center
Jaguar Health https://jaguar.health/
Napo Pharmaceuticals https://napopharma.com/
Napo Therapeutics https://napotherapeutics.com/en/
https://www.magdalenabiosciences.com/
Magdalena is a joint venture formed by Jaguar Health and Filament Health. The company holds an exclusive license to Jaguar's proprietary library of approximately 2,300 highly characterized medicinal plants and 3,500 plant extracts for designated therapeutic indications.
Visit Jaguar on LinkedIn:
https://www.linkedin.com/company/jaguar-health/
Visit Jaguar on Instagram: https://www.instagram.com/jaguarhealthcommunity/
Visit Jaguar on X: https://twitter.com/Jaguar_Health
Phone: 415-371-8300
Contact: hello@jaguar.health
Press Releases: https://jaguarhealth.gcs-web.com/news-releases
Most if not all works by mechanism chloride ions into the gut then water comes and diarrhea out. Crofelemer normalizes abnormal ion flow targeting only locally in the gut.
Jaguar has been putting the expense into making sure Crofelemer drug supply is ready to get into this opportunity to treat cancer related chemo patients since pharmacy’s already can get FDA approved, all ready in the in the supply chain in the pharmacy as Crofelemer for AIDs patients.
Research has shown it costs 3x as much to treat a cancer patient with diarrhea.
It would be better to treat the cancer patient for diarrhea with Crofelemer pending OnTarget Study and FDA approval.
Since Crofelemer is FDA approved to treat dogs for Cancer Chemo related Diarrhea it has been said:
If your going to have cancer and cancer related Diarrhea, it’s better to be a dog than a human right now.
The companies that manufacture the cancer agents/drugs sort of point to the availability of Crofelemer because it allows them to keep their patients on their therapies thereby improving their penetration and their revenues opportunity.
3rd party market research put Short Bowel Syndrome at $5-$12 Billion opportunity because these patience are so ill, high mortality, high morbidity (the state of being unhealth for a particular disease or situation), so high of expense to manage through life.
That opportunity can be reached in small trials around the world to show benefits to be able to show global development.
Product already approved, already fully in the supply chain in the pharmacy.
Potential Market of Mytesi (crofelemer)
Jaguar and Napo $JAGX if the Phase 3 OnTarget Study has good results.
The Phase 3 OnTarget Study results are due to be out soon in this quarter.
The Phase 3 OnTarget study is testing whether the company's plant-based prescription drug crofelemer can prevent or substantially reduce diarrhea and other symptoms of CIOB when any one of the selected 24 different targeted therapies that are associated with diarrhea in patients is initiated.
Each year, more than 1 million cancer patients in the United States receive chemotherapy or radiation. Globally 9.8 million require chemotherapy.
Diarrhea is a common side effect of targeted therapies. Up to 95% of patients on tyrosine kinase inhibitors (TKIs) suffer from diarrhea, depending on the TKI used.
Any drug used to treat cancer (including tyrosine kinase inhibitors or TKIs) can be considered chemo, but here chemo is used to mean treatment with conventional cytotoxic (cell-killing) drugs that mainly kill cells that are growing and dividing rapidly. Chemo was once one of the main treatments for CML.
The cost for Mytesi oral delayed release tablet 125 mg is around $2,600 for a supply of 60 tablets. This amount is the one month supply as testing in the OnTarget Study.
That is a 24 week study = 5.6 month supply needed = $14,560.00 for treatment.
Potential Market of Mytesi (crofelemer)
100,000 patients a year = $1,456,000,000
250,000 patients a year = $3,640,000,000
500,000 patients a year = $7,280,000,000
1,000,000 patients a year = $14,560,000,000 (assuming worldwide)
5,000,000 patients a year = $72,800,000,000 (assuming worldwide)
The estimate of patients depends on how many quit taking chemo, the onTarget Study, FDA approval and or quit taking Mytesi (crofelemer).
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |